{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:25:24Z","timestamp":1787243124091,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T00:00:00Z","timestamp":1652745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Hypertrophic cardiomyopathy (HCM) is a genetic disease of the sarcomere that causes otherwise unexplained cardiac hypertrophy and is associated with sudden death. While previous studies showed the role of the epigenetic modifier Brg1 in mouse models of HCM, additional work is needed to identify its role in humans. We tested the hypothesis that BRG1 expression is increased in periods of cardiac remodeling during fetal growth and in development of HCM. We employed immunohistochemical staining to evaluate protein expression of BRG1 in 796 human cardiac specimens (81 from patients with HCM) and describe elevated BRG1 expression in human fetal hearts in early development. In addition, we not only demonstrate increased expression of BRG1 in HCM, but we also show that other diseases that lead to heart failure have similar BRG1 expression to healthy controls. Inhibition of BRG1 in human induced pluripotent stem cell-derived cardiomyocytes significantly decreases\n                    <jats:italic>MYH7<\/jats:italic>\n                    and increases\n                    <jats:italic>MYH6<\/jats:italic>\n                    , suggesting a regulatory role for BRG1 in the pathological imbalance of the two myosin heavy chain isoforms in human HCM. These data are the first demonstration of BRG1 as a specific biomarker for human HCM and provide foundation for future studies of epigenetics in human cardiac disease.\n                  <\/jats:p>","DOI":"10.1038\/s41598-022-11829-x","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T10:03:37Z","timestamp":1652781817000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["BRG1 is a biomarker of hypertrophic cardiomyopathy in human heart specimens"],"prefix":"10.1038","volume":"12","author":[{"given":"Jacob C.","family":"Scherba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc K.","family":"Halushka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Maleszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Landstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenad","family":"Bursac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,17]]},"reference":[{"key":"11829_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","volume":"379","author":"BJ Maron","year":"2018","unstructured":"Maron, B. J. Clinical course and management of hypertrophic cardiomyopathy. N. Engl. J. Med. 379, 655\u2013668. https:\/\/doi.org\/10.1056\/NEJMra1710575 (2018).","journal-title":"N. Engl. J. Med."},{"key":"11829_CR2","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/circulationaha.117.033200","volume":"138","author":"CY Ho","year":"2018","unstructured":"Ho, C. Y. et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation 138, 1387\u20131398. https:\/\/doi.org\/10.1161\/circulationaha.117.033200 (2018).","journal-title":"Circulation"},{"key":"11829_CR3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/s0025-6196(11)63196-0","volume":"80","author":"SL Van Driest","year":"2005","unstructured":"Van Driest, S. L., Ommen, S. R., Tajik, A. J., Gersh, B. J. & Ackerman, M. J. Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clin. Proc. 80, 463\u2013469. https:\/\/doi.org\/10.1016\/s0025-6196(11)63196-0 (2005).","journal-title":"Mayo Clin. Proc."},{"key":"11829_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/circgen.117.001896","volume":"11","author":"HG van Velzen","year":"2018","unstructured":"van Velzen, H. G. et al. Outcomes of contemporary family screening in hypertrophic cardiomyopathy. Circ. Genom. Precis. Med. 11, e001896. https:\/\/doi.org\/10.1161\/circgen.117.001896 (2018).","journal-title":"Circ. Genom. Precis. Med."},{"key":"11829_CR5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.119.002460","volume":"12","author":"J Ingles","year":"2019","unstructured":"Ingles, J. et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. Circ. Genom. Precis. Med. 12, e002460 (2019).","journal-title":"Circ. Genom. Precis. Med."},{"key":"11829_CR6","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jchf.2018.02.010","volume":"6","author":"JB Geske","year":"2018","unstructured":"Geske, J. B., Ommen, S. R. & Gersh, B. J. Hypertrophic cardiomyopathy: Clinical update. JACC Heart Fail. 6, 364\u2013375. https:\/\/doi.org\/10.1016\/j.jchf.2018.02.010 (2018).","journal-title":"JACC Heart Fail."},{"key":"11829_CR7","doi-asserted-by":"publisher","first-page":"16034","DOI":"10.1038\/ncomms16034","volume":"8","author":"JM Vieira","year":"2017","unstructured":"Vieira, J. M. et al. BRG1-SWI\/SNF-dependent regulation of the Wt1 transcriptional landscape mediates epicardial activity during heart development and disease. Nat. Commun. 8, 16034 (2017).","journal-title":"Nat. Commun."},{"key":"11829_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nature09130","volume":"466","author":"CT Hang","year":"2010","unstructured":"Hang, C. T. et al. Chromatin regulation by Brg1 underlies heart muscle development and disease. Nature 466, 62\u201367 (2010).","journal-title":"Nature"},{"key":"11829_CR9","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Elliott, P. M. et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J. 35, 2733\u20132779 (2014).","journal-title":"Eur. Heart J."},{"key":"11829_CR10","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.jacc.2021.03.008","volume":"77","author":"H Cui","year":"2021","unstructured":"Cui, H. et al. Myocardial histopathology in patients with obstructive hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 77, 2159\u20132170. https:\/\/doi.org\/10.1016\/j.jacc.2021.03.008 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"11829_CR11","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1016\/j.jacc.2021.03.292","volume":"77","author":"EJ Rowin","year":"2021","unstructured":"Rowin, E. J. & Fifer, M. A. Evaluating histopathology to improve our understanding of hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 77, 2171\u20132173. https:\/\/doi.org\/10.1016\/j.jacc.2021.03.292 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"11829_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/hrt.20.1.1","volume":"20","author":"D Teare","year":"1958","unstructured":"Teare, D. Asymmetrical hypertrophy of the heart in young adults. Br. Heart J. 20, 1\u20138. https:\/\/doi.org\/10.1136\/hrt.20.1.1 (1958).","journal-title":"Br. Heart J."},{"key":"11829_CR13","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1161\/CIRCULATIONAHA.107.186093","volume":"116","author":"LT Cooper","year":"2007","unstructured":"Cooper, L. T. et al. The role of endomyocardial biopsy in the management of cardiovascular disease: A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 116, 2216\u20132233 (2007).","journal-title":"Circulation"},{"key":"11829_CR14","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1161\/circresaha.121.318346","volume":"128","author":"AJ Marian","year":"2021","unstructured":"Marian, A. J. Molecular genetic basis of hypertrophic cardiomyopathy. Circ. Res. 128, 1533\u20131553. https:\/\/doi.org\/10.1161\/circresaha.121.318346 (2021).","journal-title":"Circ. Res."},{"key":"11829_CR15","doi-asserted-by":"publisher","first-page":"12681","DOI":"10.1038\/s41598-019-49191-0","volume":"9","author":"TY Wang","year":"2019","unstructured":"Wang, T. Y. et al. Human cardiac myosin light chain 4 (MYL4) mosaic expression patterns vary by sex. Sci. Rep. 9, 12681. https:\/\/doi.org\/10.1038\/s41598-019-49191-0 (2019).","journal-title":"Sci. Rep."},{"key":"11829_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41569-019-0331-x","volume":"17","author":"E Karbassi","year":"2020","unstructured":"Karbassi, E. et al. Cardiomyocyte maturation: Advances in knowledge and implications for regenerative medicine. Nat. Rev. Cardiol. 17, 341\u2013359. https:\/\/doi.org\/10.1038\/s41569-019-0331-x (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"11829_CR17","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/j.biocel.2008.02.020","volume":"40","author":"SP Barry","year":"2008","unstructured":"Barry, S. P., Davidson, S. M. & Townsend, P. A. Molecular regulation of cardiac hypertrophy. Int. J. Biochem. Cell Biol. 40, 2023\u20132039. https:\/\/doi.org\/10.1016\/j.biocel.2008.02.020 (2008).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"11829_CR18","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1152\/physrev.00048.2017","volume":"98","author":"T Moore-Morris","year":"2018","unstructured":"Moore-Morris, T., van Vliet, P. P., Andelfinger, G. & Puceat, M. Role of epigenetics in cardiac development and congenital diseases. Physiol. Rev. 98, 2453\u20132475. https:\/\/doi.org\/10.1152\/physrev.00048.2017 (2018).","journal-title":"Physiol. Rev."},{"key":"11829_CR19","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41467-017-01946-x","volume":"8","author":"IY Shadrin","year":"2017","unstructured":"Shadrin, I. Y. et al. Cardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues. Nat. Commun. 8, 1825. https:\/\/doi.org\/10.1038\/s41467-017-01946-x (2017).","journal-title":"Nat. Commun."},{"key":"11829_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.actbio.2021.03.007","volume":"126","author":"RZ Zhan","year":"2021","unstructured":"Zhan, R. Z., Rao, L., Chen, Z., Strash, N. & Bursac, N. Loss of sarcomeric proteins via upregulation of JAK\/STAT signaling underlies interferon-\u03b3-induced contractile deficit in engineered human myocardium. Acta Biomater. 126, 144\u2013153. https:\/\/doi.org\/10.1016\/j.actbio.2021.03.007 (2021).","journal-title":"Acta Biomater."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11829-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11829-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11829-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T22:18:06Z","timestamp":1669328286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11829-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,17]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["11829"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-11829-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,17]]},"assertion":[{"value":"16 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7996"}}